3 Tertiary Care Campus, Heart Care Network and Diagnostic Labs Stocks With a Strong Future Roadmap: Global Health, Narayana Hrudayalaya and Metropolis Healthcare
- October 21, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Global Health, Narayana Hrudayalaya and Metropolis Healthcare: ROE of 12.6% to 17.8% and FY22 to FY26 revenue CAGR of 7.6% to 21.0%. Prices as of 20 Oct 2026.
Quick Answer
The three healthcare delivery stocks to watch are Global Health, Narayana Hrudayalaya and Metropolis Healthcare. Their return on equity ranges from 12.6% to 17.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 21.0%. Narayana Hrudayalaya leads on both return on equity at 17.8% and revenue growth at 21.0% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.
Healthcare delivery stocks follow the organisations that treat patients and test samples every day. Global Health, Narayana Hrudayalaya and Metropolis Healthcare cover a tertiary-care hospital group, an affordable cardiac and multi-specialty network and a national pathology laboratory chain.
This list covers three healthcare delivery stocks with complete current figures: Global Health, Narayana Hrudayalaya and Metropolis Healthcare. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Healthcare Delivery Stocks?
Healthcare delivery stocks are listed companies that run hospitals, clinics and laboratories. Their results depend on bed capacity, occupancy, the mix of procedures and the number of tests handled.
Healthcare Delivery Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Global Health | 1,238.1 | 33,277 | 60.3 | 59.6 | 14.1 | 0.30 |
| Narayana Hrudayalaya | 1,740.9 | 35,603 | 43.6 | 59.6 | 17.8 | 1.29 |
| Metropolis Healthcare | 519.1 | 10,780 | 53.1 | 59.6 | 12.6 | 0.15 |
On valuation, Narayana Hrudayalaya and Metropolis Healthcare trade at a P/E below the industry P/E, while Global Health trades above it, which reflects the growth the market already expects. Readers comparing healthcare delivery stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Healthcare Delivery Stocks Have a Strong Roadmap in India?
Healthcare delivery stocks have a strong roadmap in India because demand for quality treatment and testing is growing faster than the number of organised beds and laboratories.
- Insurance cover. More insured families choose organised hospitals and labs.
- New capacity. Added beds and collection centres in proven cities lift volumes.
- Complex care. Cardiac, cancer and transplant care draws patients to specialist centres.
Why Global Health Features Among These Healthcare Delivery Stocks
Among the healthcare delivery stocks on this list, Global Health, which operates the Medanta brand, runs tertiary-care hospitals led by its flagship campus in Gurugram, along with facilities in Lucknow, Patna, Ranchi, Indore and Noida.
In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%.
Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6.
Roadmap: Management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.
What to watch: Watch the ramp-up speed of newer hospitals and the pace of doctor additions at each site.
Why Narayana Hrudayalaya Features Among These Healthcare Delivery Stocks
Among the hospital and laboratory shares on this list, Narayana Hrudayalaya, widely known as Narayana Health, is a Bengaluru-based hospital group built around affordable cardiac care that now covers multiple specialities across India and also operates in the Cayman Islands.
The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6.
Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%.
Roadmap: Growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.
What to watch: Keep an eye on occupancy in newly added beds and the payor mix between insurance and cash patients.
Why Metropolis Healthcare Features Among These Healthcare Delivery Stocks
Among the three companies on this list, Metropolis Healthcare, headquartered in Mumbai, is a pathology and diagnostics company that runs a national network of laboratories, patient service centres and collection points, and also serves hospitals and corporate clients.
Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%.
In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P/E of 53.1, below the industry P/E of 59.6.
Roadmap: The company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.
What to watch: Follow test volumes per patient and the pace at which newer regions turn profitable.
Global Health vs Narayana Hrudayalaya vs Metropolis Healthcare on Key Financials
The table below sets the three healthcare delivery stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Global Health | 2,206 | 4,509 | 19.6% | 554 | 12.3% |
| Narayana Hrudayalaya | 3,736 | 7,996 | 21.0% | 810 | 10.1% |
| Metropolis Healthcare | 1,246 | 1,671 | 7.6% | 191 | 11.4% |
Narayana Hrudayalaya posts the highest return on equity in this group at 17.8%. Narayana Hrudayalaya combines the largest FY26 revenue at Rs 7,996 crore with the fastest revenue growth, a 21.0% compound annual rate. A useful habit with healthcare delivery stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Healthcare Delivery Stocks
Every theme carries risks that deserve a check before any decision. For these healthcare delivery stocks, the main points are:
- Ramp-up timing. New hospitals take time to reach stable occupancy.
- Doctor availability. Expert doctors are central to growth and hard to attract.
- Pricing rules. Changes in tariffs or price limits can affect revenue per patient.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter healthcare delivery stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Healthcare Delivery Stocks
Healthcare delivery stocks suit investors who follow bed additions, occupancy and test volumes. Global Health, Narayana Hrudayalaya and Metropolis Healthcare each have a visible expansion path. Based on the 20 October 2026 close, Global Health trades at Rs 1,238.1, Narayana Hrudayalaya at Rs 1,740.9 and Metropolis Healthcare at Rs 519.1.
Download the Univest iOS App or Univest Android App to track healthcare delivery stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are healthcare delivery stocks?
Ans. Healthcare delivery stocks are listed companies that run hospitals, clinics and laboratories. Their results depend on bed capacity, occupancy, the mix of procedures and the number of tests handled. This list looks at three of them, Global Health, Narayana Hrudayalaya and Metropolis Healthcare, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.
Which healthcare delivery stocks are covered in this list?
Ans. This list covers Global Health, Narayana Hrudayalaya and Metropolis Healthcare. Based on the 20 October 2026 close, Global Health traded at Rs 1,238.1, Narayana Hrudayalaya at Rs 1,740.9 and Metropolis Healthcare at Rs 519.1. Their return on equity ranges from 12.6% to 17.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 21.0%.
Why do healthcare delivery stocks have a strong future roadmap in India?
Ans. Healthcare delivery stocks have a strong roadmap in India because demand for quality treatment and testing is growing faster than the number of organised beds and laboratories. The main drivers are as follows. Insurance cover. More insured families choose organised hospitals and labs. New capacity. Added beds and collection centres in proven cities lift volumes. Complex care. Cardiac, cancer and transplant care draws patients to specialist centres. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Global Health performed financially?
Ans. Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6. Looking ahead, management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.
How has Narayana Hrudayalaya performed financially?
Ans. Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%. The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6. Looking ahead, growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.
How has Metropolis Healthcare performed financially?
Ans. Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%. In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P/E of 53.1, below the industry P/E of 59.6. Looking ahead, the company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.
What risks should investors check before buying healthcare delivery stocks?
Ans. Investors should check a few risks before buying healthcare delivery stocks. Ramp-up timing. New hospitals take time to reach stable occupancy. Doctor availability. Expert doctors are central to growth and hard to attract. Pricing rules. Changes in tariffs or price limits can affect revenue per patient. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of healthcare delivery stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
